Short Interest in Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Declines By 34.5%

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 43,251 shares, a drop of 34.5% from the August 15th total of 66,082 shares. Currently, 3.3% of the company’s shares are sold short. Based on an average daily volume of 23,843 shares, the days-to-cover ratio is currently 1.8 days.

Aspire Biopharma Stock Performance

Shares of NASDAQ:ASBP opened at $8.54 on Friday. Aspire Biopharma has a 1 year low of $3.31 and a 1 year high of $562.92. The stock has a market capitalization of $11.96 million, a P/E ratio of -0.12 and a beta of 0.17. The stock has a 50-day simple moving average of $7.74 and a 200-day simple moving average of $12.47.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Aspire Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Aspire Biopharma currently has an average rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma, Inc is a clinical-stage biopharmaceutical company developing drug-delivery products based on proprietary oral thin-film technology. Its platform is designed to deliver medication through the mouth without requiring water or conventional swallowing, with the goal of enabling rapid absorption and improving ease of use.

The company’s lead development program is an orally administered aspirin product intended for potential use in acute cardiovascular situations, where rapid delivery may be important.